IXICO plc Late phase clinical study in Huntington's disease
March 05 2019 - 1:02AM
RNS Non-Regulatory
TIDMIXI
IXICO plc
05 March 2019
5(th) March
IXICO plc
("IXICO" or the "Company")
IXICO continues to be first choice for imaging services in
Huntington's disease
Chosen to support a late phase clinical research programme,
adding GBP0.5m in revenues
IXICO plc (AIM: IXI), the data analytics company delivering
insights in neuroscience, today announces that it has been
confirmed as the provider of data analytics and neuroimaging
services to support the ongoing treatment of participants in a late
phase clinical research programme in Huntington's disease. IXICO's
unique service offering and expertise will be employed in an
extension study to allow people living with the disease to continue
to contribute to the search for a treatment for this condition.
The agreement, which accentuates IXICO's momentum in
Huntington's disease, will generate additional revenues of GBP0.5m
during the course of the study.
Giulio Cerroni, Chief Executive Officer of IXICO, commented:
"We are pleased to announce our involvement in this late phase
clinical study, which supports the search for an effective
treatment of Huntington's disease. The announcement emphasises our
partner-of-choice status in neurodegenerative data analytics and
our capabilities across all stages of clinical development."
For further information please contact:
IXICO plc
Giulio Cerroni, Chief Executive Officer Tel: +44 20 3763 7498
FTI Consulting Limited (Investor Relations) Tel: +44 20 3727 1000
Simon Conway / Victoria Foster Mitchell / Tim Stamper
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our
mission is to transform the progression of our biopharmaceutical
clients' neurological therapeutic pipelines through the application
of novel medical imaging and mobile health digital
technologies.
IXICO's data analytics services are used by the global
biopharmaceutical industry to interpret data from brain scans and
digital biosensors to enable better trial design, site
qualification, patient selection and clinical outcomes. We provide
technology-enabled services across all phases of clinical
evaluation. Our integrated digital platform provides a scalable and
secure infrastructure for the capture and analysis of regulatory
compliant clinical data to enable clients to make rapid, better
informed decisions. IXICO is also collaborating with partners to
develop new analytical techniques and companion digital health
products targeted at improving patient outcomes.
More information is available on www.IXICO.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAUGUMPWUPBGPC
(END) Dow Jones Newswires
March 05, 2019 02:02 ET (07:02 GMT)
Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2024 to May 2024
Ixico (LSE:IXI)
Historical Stock Chart
From May 2023 to May 2024